Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction

OBJECTIVES: C5 inhibitors such as eculizumab and ravulizumab are the first-line treatment in the management of paroxysmal nocturnal hemoglobinuria (PNH). However, some patients develop novel symptoms as part of their treatment with eculizumab, and the disease is termed as eculizumab refractory PNH....

Descripción completa

Detalles Bibliográficos
Autores principales: Syed, Saad, Khan, Reda, Khurram, Fahmida, Khan, Faiza Humayun, Safi, Danish, Safi, Salah Ud Din
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302528/
https://www.ncbi.nlm.nih.gov/pubmed/37388903
http://dx.doi.org/10.1177/20503121231181267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302528/
https://www.ncbi.nlm.nih.gov/pubmed/37388903
http://dx.doi.org/10.1177/20503121231181267

Ejemplares similares